小柯机器人

英国美国国家心肺研究所Mohamed H. Shamji研究组取得最新进展。他们提出过敏原免疫疗法诱导产生白细胞介素10生产型2先天淋巴样细胞（IL-10 + ILC2s）与临床反应相关。相关论文于2021年1月14日发表于国际顶尖学术期刊《免疫学》杂志上。

他们报告IL-10 + ILC2s在调节草粉过敏中的作用。他们证明，用IL-33和视黄酸激活后，KLRG1 +而不是KLRG1-ILC2产生IL-10。这些细胞减弱Th反应并维持上皮细胞完整性。与健康受试者相比，草粉过敏患者的IL-10 + KLRG1 + ILC2s更低。

在一项前瞻性、双盲、安慰剂对照试验中，他们证明了接受草粉舌下免疫治疗的患者，ILC2产生IL-10的效力得以恢复。支撑机制与ILCs中视黄醇代谢途径，细胞因子-细胞因子受体相互作用和JAK-STAT信号途径的修饰有关。总之，他们的发现强调了过敏原免疫疗法中，IL-10 + ILC2s在疾病缓解作用中的作用。

据悉，尚不清楚先天免疫细胞在过敏原免疫疗法中赋予敏化过敏原免疫耐受的作用。

附：英文原文

Title: Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response

Author: Korneliusz Golebski, Janice A. Layhadi, Umit Sahiner, Esther H. Steveling-Klein, Madison M. Lenormand, Rachael C.Y. Li, Suzanne M. Bal, Balthasar A. Heesters, Gemma Vilà-Nadal, Oliver Hunewald, Guillem Montamat, Feng Q. He, Markus Ollert, Oleksandra Fedina, Mongkol Lao-Araya, Susanne J.H. Vijverberg, Anke-Hilse Maitland-van der Zee, Cornelis M. van Drunen, Wytske J. Fokkens, Stephen R. Durham, Hergen Spits, Mohamed H. Shamji

Issue&Volume: 2021-01-14

Abstract: The role of innate immune cells in allergen immunotherapy that confers immune toleranceto the sensitizing allergen is unclear. Here, we report a role of interleukin-10-producingtype 2 innate lymphoid cells (IL-10+ ILC2s) in modulating grass-pollen allergy. We demonstrate that KLRG1+ but not KLRG1– ILC2 produced IL-10 upon activation with IL-33 and retinoic acid. These cells attenuatedTh responses and maintained epithelial cell integrity. IL-10+ KLRG1+ ILC2s were lower in patients with grass-pollen allergy when compared to healthy subjects.In a prospective, double-blind, placebo-controlled trial, we demonstrated that thecompetence of ILC2 to produce IL-10 was restored in patients who received grass-pollensublingual immunotherapy. The underpinning mechanisms were associated with the modificationof retinol metabolic pathway, cytokine-cytokine receptor interaction, and JAK-STATsignaling pathways in the ILCs. Altogether, our findings underscore the contributionof IL-10+ ILC2s in the disease-modifying effect by allergen immunotherapy.

DOI: 10.1016/j.immuni.2020.12.013

Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30541-0

Immunity：《免疫》，创刊于1994年。隶属于细胞出版社，最新IF：43.474
官方网址：https://www.cell.com/immunity/home
投稿链接：https://www.editorialmanager.com/immunity/default.aspx